King's College London

Funding Information: C.R.‐B. has nothing to disclose. A.S., research funding or support from University College London, National Institute of Health (NIHR), National Institute for Health Research ULCH Biomedical Research Centre, the International Parkinson and Movement Disorder Society (IPMDS), the European Commission, Parkinson's UK, GE Healthcare and the Economic and Social Research Council. Advisory board or consultancy from Biogen, Abbvie, Roche, Bial, GE Healthcare; and Royalties from Oxford University Press. A.R. has received salary support from the National institute of Health Research (NIHR) Clinical Research Network (CRN) South London, Guy's Hospital, Great Maze Pond, London UK and honorarium from Britannia Pharmaceuticals Ltd, UK. K.R.C., Advisory board: AbbVie, UCB, GKC, Bial, Cynapsus, Novartis, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Therevance, Scion, Britannia. Honoraria for lectures: AbbVie, Britannia, UCB, Mundipharma, Zambon, Novartis, Boeringer Ingelheim. Grants (Investigator Initiated): Britania Pharmaceuticals, AbbVie, UCB, GKC, Bial, Academic grants: EU, IMI EU, Horizon 2020, Parkinson's UK, NIHR, PDNMG, EU (Horizon 2020), Kirby Laing Foundation, NPF, MRC, Wellcome Trust. P.M.‐M., honoraria from National School of Public Health (ISCIII), Britannia, and Editorial Viguera for lecturing in courses; International Parkinson and Movement Disorder Society for management of the Program on Rating Scales; and Bial for advice in clinical‐epidemiological studies. Financial support by the International Parkinson and Movement Disorder Society for attending the IPMDS International Congress 2019. Research grant from the International Parkinson and Movement Disorder Society, for development and validation of the MDS‐NMS. D.W., research funding or support from Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Therapeutic Research Initiative (ATRI), Alzheimer's Disease Cooperative Study (ADCS), the International Parkinson and Movement Disorder Society (IPMDS), and National Institute on Aging (NIA); honoraria for consultancy from Acadia, CHDI Foundation, Clintrex LLC (Aptinyx, Avanir, Otsuka), Eisai, Janssen, Sage, Signant Health and Sunovion; and license fee payments from the University of Pennsylvania for the QUIP and QUIP‐RS. Funding Information: PMM is Co‐Chair of the Program on Rating Scales of the IPMDS. The project was supported by a two‐stage academic peer‐reviewed grant from the International Parkinson's and Movement Disorder's Society (IPMDS) as well as Clinical Research Network (CRN), London South and London North Thames, National Institute of Health Research (for the UK sites). Funding Information: The authors acknowledge grant support from the International Parkinson and Movement Disorder Society to plan, develop, and validate the English version of the MDS‐NMS in an international study. K.R.C. acknowledges support from the NIHR clinical research network and CRN‐supported staff (Dhaval Trivedi, Aleksandra Podlewska, Corinne Borley) for data collection in NHS clinics. A.S. was supported by the National Institute for Health Research UCLH Biomedical Research Centre. D.W. acknowledges the support of the Parkinson's Disease and Movement Disorders Center at the University of Pennsylvania School of Medicine and the involvement of Dr. Jacqui Rick, Sam Rudovsky, and Benjamin Deck in the conduct of the study. This article also presents independent research partly funded by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London, as K.R.C. is funded by these institutions. The views expressed are those of the author and not necessarily those of the NHS, the NIHR, or the Department of Health. Publisher Copyright: © 2020 International Parkinson and Movement Disorder Society Copyright: Copyright 2021 Elsevier B.V., All rights reserved.